{"log_id": 369382459229633053, "direction": 0, "words_result_num": 33, "words_result": [{"probability": {"variance": 0.057226, "average": 0.625892, "min": 0.386672}, "location": {"width": 56, "top": 24, "height": 31, "left": 1159}, "words": "比"}, {"probability": {"variance": 0, "average": 0.704266, "min": 0.704266}, "location": {"width": 29, "top": 65, "height": 35, "left": 1159}, "words": "牛"}, {"probability": {"variance": 0.00011, "average": 0.997121, "min": 0.93462}, "location": {"width": 855, "top": 123, "height": 50, "left": 183}, "words": "虽然还没有依那西普用于多发性硬化症患者的临床试验,但其他TNF抑制剂对多发性"}, {"probability": {"variance": 5e-06, "average": 0.998424, "min": 0.991436}, "location": {"width": 854, "top": 172, "height": 49, "left": 183}, "words": "硬化症患者的临床试验显示疾病活动性有所增加。当对曾经或正患有中枢神经系统脱髓"}, {"probability": {"variance": 0.00059, "average": 0.994645, "min": 0.847319}, "location": {"width": 854, "top": 222, "height": 49, "left": 183}, "words": "鞘疾病的患者或者被认为可能增加出现脱髓鞘疾病风险的患者开立处方时,应建议进行"}, {"probability": {"variance": 0.005595, "average": 0.982054, "min": 0.656052}, "location": {"width": 439, "top": 282, "height": 39, "left": 183}, "words": "包括神经系统评估在内的详细风险/受益评估"}, {"probability": {"variance": 2e-06, "average": 0.998529, "min": 0.996506}, "location": {"width": 92, "top": 339, "height": 29, "left": 183}, "words": "联合治疗"}, {"probability": {"variance": 2.9e-05, "average": 0.997944, "min": 0.969123}, "location": {"width": 815, "top": 372, "height": 48, "left": 228}, "words": "在类风湿关节炎患者中进行为期2年的对照临床试验表明,依那西普与甲氨蝶呤联"}, {"probability": {"variance": 2.9e-05, "average": 0.998203, "min": 0.965844}, "location": {"width": 861, "top": 422, "height": 48, "left": 182}, "words": "合使用不会导致非预期的安全性事件,且依那西普与甲氨蝶呤联合使用的安全性特点与"}, {"probability": {"variance": 1.8e-05, "average": 0.997628, "min": 0.97834}, "location": {"width": 861, "top": 471, "height": 48, "left": 182}, "words": "依那西普或甲氨蝶呤单独使用时报告的安全性特点相似。目前正在进行长期联合用药安"}, {"probability": {"variance": 4.3e-05, "average": 0.997896, "min": 0.960687}, "location": {"width": 860, "top": 521, "height": 48, "left": 183}, "words": "全性特点的评估。依那西普与其他改善病情的抗风湿药物( DMARD)共同使用时,恩"}, {"probability": {"variance": 2e-06, "average": 0.998542, "min": 0.99516}, "location": {"width": 255, "top": 583, "height": 34, "left": 182}, "words": "利的长期安全性还未确定"}, {"probability": {"variance": 1.2e-05, "average": 0.998147, "min": 0.982603}, "location": {"width": 685, "top": 621, "height": 46, "left": 227}, "words": "尚未进行依那西普与银屑病的其他系统疗法或光疗法共同使用的研究"}, {"probability": {"variance": 1.4e-05, "average": 0.997591, "min": 0.988619}, "location": {"width": 165, "top": 684, "height": 28, "left": 181}, "words": "肾和肝功能不全"}, {"probability": {"variance": 5.4e-05, "average": 0.998056, "min": 0.954968}, "location": {"width": 824, "top": 717, "height": 47, "left": 225}, "words": "根据药代动力学资料(参见“药代动力学”),肝或肾功能不全患者无需进行剂量"}, {"probability": {"variance": 1.2e-05, "average": 0.997819, "min": 0.98705}, "location": {"width": 371, "top": 776, "height": 36, "left": 182}, "words": "调整;针对这些患者的临床经验有限"}, {"probability": {"variance": 4e-06, "average": 0.99839, "min": 0.995178}, "location": {"width": 163, "top": 829, "height": 31, "left": 183}, "words": "充血性心力衰竭"}, {"probability": {"variance": 3.5e-05, "average": 0.996338, "min": 0.968309}, "location": {"width": 821, "top": 862, "height": 49, "left": 228}, "words": "心力衰竭(CHF)患者使用依那西普时,医师应特别谨慎。上市后曾有使用依那西"}, {"probability": {"variance": 1.7e-05, "average": 0.998165, "min": 0.975526}, "location": {"width": 867, "top": 912, "height": 47, "left": 182}, "words": "普的患者在有或无明显促发因素的情况下出现充血性心力衰竭加重的报告。两项用于评"}, {"probability": {"variance": 4e-05, "average": 0.998226, "min": 0.960884}, "location": {"width": 870, "top": 960, "height": 49, "left": 181}, "words": "价依那西普治疗心力衰竭患者的大规模临床试验因缺乏疗效而终止。尽管不是最终结"}, {"probability": {"variance": 4e-06, "average": 0.998775, "min": 0.990718}, "location": {"width": 870, "top": 1009, "height": 48, "left": 181}, "words": "论,但其中一项试验的资料显示使用依那西普治疗的患者可能存在加重充血性心力衰竭"}, {"probability": {"variance": 1e-06, "average": 0.999343, "min": 0.99832}, "location": {"width": 69, "top": 1076, "height": 25, "left": 183}, "words": "的倾向"}, {"probability": {"variance": 0.015243, "average": 0.939138, "min": 0.637447}, "location": {"width": 207, "top": 1119, "height": 36, "left": 181}, "words": " Wegener's氏肉芽肿"}, {"probability": {"variance": 3e-06, "average": 0.998884, "min": 0.992578}, "location": {"width": 825, "top": 1153, "height": 48, "left": 227}, "words": "在一项平均持续时间为25个月安慰剂对照试验中,89名成年患者接受依那西普和"}, {"probability": {"variance": 0.006557, "average": 0.973646, "min": 0.540834}, "location": {"width": 878, "top": 1201, "height": 51, "left": 180}, "words": "标准疗法(包括环磷酰胺、甲氨蝶呤和糖皮质激素),结果并未显示依那西普对 wegener's"}, {"probability": {"variance": 2.7e-05, "average": 0.998457, "min": 0.967182}, "location": {"width": 877, "top": 1252, "height": 49, "left": 179}, "words": "氏肉芽肿的治疗有效。依那西普治疗组出现各种类型非皮肤恶性肿瘤的发生率显著高于"}, {"probability": {"variance": 0.008209, "average": 0.974533, "min": 0.555926}, "location": {"width": 614, "top": 1297, "height": 52, "left": 180}, "words": "对照组。不推荐使用依那西普治疗 Wegener's氏肉芽肿。"}, {"probability": {"variance": 2.1e-05, "average": 0.997462, "min": 0.984501}, "location": {"width": 244, "top": 1411, "height": 35, "left": 186}, "words": "孕妇及哺乳期妇女用药"}, {"probability": {"variance": 7e-06, "average": 0.99846, "min": 0.986001}, "location": {"width": 830, "top": 1447, "height": 48, "left": 226}, "words": "没有开展妊娠妇女使用依那西普的研究,因此尚未建立妊娠妇女使用依那西普的安"}, {"probability": {"variance": 1.3e-05, "average": 0.998517, "min": 0.978254}, "location": {"width": 876, "top": 1497, "height": 47, "left": 181}, "words": "全性。在大鼠和家兔中进行的发育毒性研究中未发现依那西普对胎崽的损害。还没有关"}, {"probability": {"variance": 1e-06, "average": 0.999234, "min": 0.995996}, "location": {"width": 877, "top": 1545, "height": 48, "left": 180}, "words": "于依那西普的围产期和产后毒性以及依那西普对生育力和生殖能力的影响的临床前数"}, {"probability": {"variance": 0.000518, "average": 0.98518, "min": 0.935866}, "location": {"width": 166, "top": 1612, "height": 26, "left": 181}, "words": "版本号:20090118"}, {"probability": {"variance": 3e-06, "average": 0.996945, "min": 0.994239}, "location": {"width": 180, "top": 1596, "height": 30, "left": 793}, "words": "第13页共31页"}], "language": 3}